Related Experiment Video
Updated: Aug 30, 2025
Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity
Published on: October 25, 2016
CD36-Binding Amphiphilic Nanoparticles for Attenuation of Alpha Synuclein-Induced Microglial Activation
Nanxia Zhao1, Nicola L Francis2, Shuang Song3
1Department of Chemical and Biochemical Engineering, 98 Brett Rd, Rutgers University, NJ, 08854 USA.
Abstract:
Neuroinflammation is one of the hallmarks contributing to Parkinson's Disease (PD) pathology, where microglial activation occurs as one of the earliest events, triggered by extracellular alpha synuclein (aSYN) binding to the CD36 receptor. Here, CD36-binding nanoparticles (NPs) containing synthetic tartaric acid-based amphiphilic polymers (AMs) were rationally designed to inhibit this aSYN-CD36 binding. In silico docking revealed that four AMs with varying alkyl side chain lengths presented differential levels of CD36 binding affinity and that an optimal alkyl chain length would promote the strongest inhibitory activity towards aSYN-CD36 interactions. In vitro competitive binding assays indicated that the inhibitory activity of AM-based NPs plateaued at intermediate side chain lengths of 12- and 18-carbons, supporting the in silico docking predictions. These 12- and 18-carbon length AM NPs also had significantly stronger effects on reducing aSYN internalization and inhibiting the production of the proinflammatory molecules TNF-α and nitric oxide from aSYN-challenged microglia. All four NPs modulated the gene expression of aSYN-challenged microglia, downregulating the expression of the proinflammatory genes TNF, IL-6, and IL-1β, and upregulating the expression of the anti-inflammatory genes TGF-β and Arg1. Overall, this work represents a novel polymeric nanotechnology platform that can be used to modulate aSYN-induced microglial activation in PD.
Insights
Novel nanoparticles targeting alpha synuclein (aSYN) binding to CD36 receptors effectively reduce neuroinflammation in Parkinson's Disease models. This nanotechnology platform modulates microglial activation, offering a new therapeutic strategy for PD.
Area of Science:
- Neuroscience
- Nanotechnology
- Immunology
Background:
- Neuroinflammation, driven by microglial activation, is a key factor in Parkinson's Disease (PD) pathology.
- Extracellular alpha synuclein (aSYN) binding to the CD36 receptor initiates microglial activation in PD.
Purpose of the Study:
- To design and evaluate CD36-binding nanoparticles (NPs) capable of inhibiting aSYN-CD36 interactions.
- To investigate the potential of these NPs as a therapeutic strategy for modulating aSYN-induced microglial activation in PD.
Main Methods:
- In silico docking studies to predict CD36 binding affinity of tartaric acid-based amphiphilic polymer (AM) nanoparticles with varying alkyl chain lengths.
- In vitro competitive binding assays to assess NP inhibitory activity against aSYN-CD36 binding.
- Experiments to evaluate the effects of AM NPs on aSYN internalization and pro-inflammatory molecule production in microglia.
- Analysis of gene expression changes in aSYN-challenged microglia treated with AM NPs.
Main Results:
- In silico and in vitro studies identified optimal alkyl chain lengths (12- and 18-carbons) for AM NPs to inhibit aSYN-CD36 binding.
- AM NPs significantly reduced aSYN internalization and the production of pro-inflammatory molecules (TNF-α, nitric oxide) in microglia.
- All tested NPs modulated microglial gene expression, downregulating pro-inflammatory markers (TNF, IL-6, IL-1β) and upregulating anti-inflammatory markers (TGF-β, Arg1).
Conclusions:
- A novel polymeric nanotechnology platform using AM NPs effectively inhibits aSYN-induced microglial activation.
- These NPs demonstrate potential for therapeutic intervention in Parkinson's Disease by targeting neuroinflammation.
- The study highlights the promise of rationally designed nanoparticles for modulating specific molecular interactions in neurodegenerative diseases.
